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Steatotic liver grafts represent the most common type of
‘‘extended criteria’’ organs that have been introduced during
the last two decades due to the disparity between liver transplant
candidates and the number available organs. A precise deﬁnition
and reliable and reproducible method for steatosis quantiﬁcation
is currently lacking and the potential inﬂuence of the chemical
composition of hepatic lipids has not been addressed. In our view,
these shortcomings appear to contribute signiﬁcantly to the
inconsistent results of studies reporting on graft steatosis and
the outcome of liver transplantation. In this review, various def-
initions, prevalence and methods of quantiﬁcation of liver steato-
sis will be covered. Ischemia/reperfusion injury of the steatotic
liver and its consequences on post-transplant outcome will be
discussed. Selection criteria for organ allocation and a number
of emerging protective strategies are suggested.
 2010 European Association for the Study of the Liver. Published
by Elsevier B.V. All rights reserved.Introduction
The lack of available organs for liver transplantation (LT) associ-
ated with the increased death rates among patients on most
waiting lists for LT has triggered the use of so-called extended cri-
teria donor (ECD) grafts, previously called ‘‘suboptimal grafts’’.
Among the wide range of these ECD livers, hepatic steatosis is
one of the most frequent disorders [1], which is mostly related
to an increasing prevalence of non-alcoholic fatty liver disease
(NAFLD). The decision to implant or reject a steatotic liver for
LT, however, is difﬁcult due to a risk of impaired graft function
or even failure after implantation. How much and what types
of fat represent a signiﬁcant risk for primary non functionJournal of Hepatology 20
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donor.ﬁrst highlight the relevance of NAFLD in the general population
and its implication for LT. Second, we will present the various his-
tological designations of steatosis including recent data on the
validity of the assessment of steatosis through histologic assess-
ment. Third, we will summarize the mechanisms of injury related
to fat deposits in the liver and analyze the risk of implanting a
steatotic graft in a LT recipient. Finally, we will attempt to sum-
marize selection criteria for organ allocation, as well as recent
protective strategies.Prevalence and implications of NAFLD in liver transplantation
NAFLD is the most common cause of chronic liver disease, affect-
ing up to 30% of individuals in Western countries, and 70–80% of
obese individuals [2,3]. In a series of 73 patients who were sched-
uled for major liver resection, we found variable degrees of hepa-
tic steatosis in approximately 50% of patients [4]. In deceased
organ donors, liver steatosis has been documented in up to 30%
during the 1990th [5–7]. The risk factors for NAFLD include dia-
betes mellitus, obesity, hypertriglyceridemia, and sedentary life
style [8], and encompass a spectrum of distinct histological enti-
ties. The relevance of steatosis ranges from simple and asymp-
tomatic fat accumulation in the hepatocytes to liver steatosis
with necro-inﬂammatory components (non-alcoholic steatohep-
atitis, NASH), that may lead to ﬁbrosis. Cirrhosis develops in up
to 20% of those cases with a risk of liver failure or hepatocellular
carcinoma [9]. Therefore, the increasing prevalence of NAFLD is
expected to raise the number of LT candidates, and possibly
become the most common indication for LT.
The ﬁrst event in NAFLD genesis is liver fat accumulation
induced by changes in lipid metabolism favoring excessive tri-
glyceride accumulation in hepatocytes, as a result of insulin resis-
tance [2,3,10]. The second step is characterized by the excessive
production of reactive oxygen species (ROS), generated by mito-
chondria and cytochrome P-450 system in fatty hepatocytes [11].
New insights have been recently provided regarding the fat
composition in steatotic livers, particularly theX-3 andX-6 fatty
acids (FA) ratio [10]. In this context, X-3 FAs downregulate the
sterol regulatory element binding protein-1; a transcription
factor which enhances hepatic triglyceride accumulation via the
up-regulation of lipogenic genes such as fatty acid synthase
and stearoyl Co-A desaturase-1. Moreover, X-3 FAs upregulate
peroxisomal proliferator activated receptor-a, which stimulates
hepatic fatty acid oxidation and transcription of fatty acid11 vol. 54 j 1055–1062
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degradation genes such as mitochondrial carnitine palmitoyl
transferase-1 and peroxisomal acyl-CoA oxidase. Conversely,
these actions can be offset by excessive intake of X-6 FAs [10].Hepatic steatosis: deﬁnition and types
Steatosis is typically characterized quantitatively and qualita-
tively. The quantitative evaluation is based on the percentage of
hepatocytes containing cytoplasmic fat inclusions. In the clinical
setting, steatosis is usually reported as mild, moderate, or severe,
if, respectively less than 30%, between 30% and 60%, or more than
60% of hepatocytes contain fat vacuoles within the cytoplasm
[1,12,13]. In addition, fatty inﬁltration is separated quantitatively
into two categories, macro and microsteatosis. Macrosteatosis
(MaS) is characterized by a single, bulky fat vacuole in hepato-
cytes, displacing the nucleus to the edge of the cell. This type is
most commonly associated with obesity, diabetes, hyperlipid-
emia, and alcohol abuse. The underlying pathogenesis is related
to an excessive triglyceride accumulation in the liver, mainly
due to an increased uptake of fatty acids released from adipose
tissue and/or an augmented de novo synthesis [1,12,13]. Addi-
tionally, a defective hepatic export, caused by reduced lipopro-
tein synthesis or impaired b-oxidation of fatty acids, further
increases hepatic triglyceride content [14].
In microsteatosis (MiS), the cytoplasm of the hepatocytes con-
tains tiny lipid vesicles without nuclear dislocation. MiS is usu-
ally encountered in mitochondrial disruption following acute
viral, toxin- or drug-induced injury, sepsis, and in some metabolic
disorders [15]. Importantly, other histo-pathological features
should be carefully assessed in the presence of steatosis including
inﬂammation, ﬁbrosis, and ballooning degeneration [15,16]. MaS
alone is exceptional, most often MaS and MiS present simulta-
neously at different degrees in the liver.Assessment of fatty liver grafts
The assessment of donor liver fat is a difﬁcult task for the trans-
plant team. An initial evaluation, based on visual inspection and
palpation, is ﬁrst done during procurement of the graft in the
donor. However, criteria such as color and texture of the graft
depend solely on the experience of the explanting surgeon, and
thus remain subjective. A recent German study analyzing
explanted, but not transplanted livers, conﬁrmed that neither
preoperative evaluation by ultrasound nor macroscopic evalua-
tion during harvesting were reliable in steatosis evaluation
[17]. Imaging modalities like CT or MRI may help in a more objec-
tive assessment of hepatic fat, but such information is rarely
available before procurement [18].
The gold standard to assess hepatic steatosis is a histological
analysis by a pathologist [15,16]. Despite this general agreement,
a European survey showed that liver biopsy at the time of pro-
curement for LT is rarely performed [19]. Only 23% of liver trans-
plant recipients in the United Network for Organ Sharing (UNOS)
had a liver donor biopsy recorded. Half of the transplant surgeons
in the UK never integrate a liver biopsy into their decision-
making process [20]. However, several transplant programs con-
sider a liver biopsy mandatory before discarding a potential liver
graft [17,19,21]. As another strategy, 38% of liver transplant sur-
geons in the UK and 47% in the US proceed with the histological1056 Journal of Hepatology 2011examination of the graft, when steatosis is suspected at inspec-
tion at the time of procurement [20].
Besides different practices regarding the biopsy procedure
itself, another shortcoming is the variability in interpreting the
histological assessment. Staining techniques can affect detection
and grading of steatosis. Sample size errors that lead to mislead-
ing interpretation may be related to focal steatosis, hypersteato-
sis, or hepatic fatty sparing [16]. In this context, an autopsy study
demonstrated that the addition of a second biopsy from the
opposite hepatic lobe provides more accurate information, due
to the heterogeneity of fat distribution within the liver. Two
biopsy cores from the right and left liver were regarded to best
predict overall liver histological characteristics (correlated with
average ﬁndings in the liver, spearman correlation coefﬁcient of
0.95) [22].
In addition, a recent study conﬁrmed that H&E-stained frozen
biopsy overestimates MiS but underestimates MaS, when com-
pared with permanent sections using more speciﬁc staining
modality [23]. Therefore, it can be argued that a signiﬁcant bias
in most studies investigating fatty livers has been the use of only
H&E-stained frozen biopsy specimens [13]. Alternative methods
to detect steatosis with higher sensitivity are Sudan-III, toluidine
blue, and oil red O staining [12,15,16,20,24], but are rarely used
in the decision process of using or not a potential graft.
The assessment of fat in biopsies by pathologists, irrespective
of the staining used, bears another shortcoming. A recent study
showed a signiﬁcant inter-observer variability among experts
for both quantitative and qualitative assessments of the histo-
logic features of liver steatosis [16]. For instance, marked
(P30%) steatosis was diagnosed in 22–46% of patients by various
blinded pathologists. Furthermore, signiﬁcant disagreement was
found regarding the features and overall diagnosis of steato-hep-
atitis. To minimize this inter-observer variability, computerized
programs have been developed to more objectively quantitate
hepatic steatosis by determining the area occupied by lipid drop-
lets in a given ﬁeld of a liver section [16]. However, these quan-
titative methods provide information only on the total amount of
fat, omitting any data on the chemical composition of hepatic lip-
ids. Therefore, novel and objective tools, such as measurement of
the X-6 and X-3 FAs and prostanoid levels in liver biopsy sam-
ples, may help prediction of the magnitude of reperfusion injury,
as described below [15].Reperfusion injury in the steatotic liver graft
Several experimental studies have shown increased reperfusion
injury in a variety of models of liver steatosis [13,25,26]. For
example, hepatic arterial ﬂow and microcirculation are signiﬁ-
cantly impaired in steatotic compared with lean rats [27]. The
contribution of hepatic lipid composition was recently high-
lighted. The metabolism of dihomo-c-linolenic, arachidonic
(X-6), and eicosapentaenoic X-3) acids result in the synthesis of
vasoactive mediators impacting on liver microcirculation [10].
For example, the release of long chain fatty acids from cell mem-
branes which is triggered by phospholipase A2 and the further
metabolism by cyclooxygenase and the lipoxygenase enzymes
results in the synthesis of particular X-6 and X-3 prostanoids.
Products of the cyclooxygenase pathway include prostaglandins
(PGs) and thromboxanes (TXs), while leukotrienes (LTs) are syn-
thesized through lipooxygenase-mediated reactions. Abnormallyvol. 54 j 1055–1062
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elevatedX-6:X-3 FA ratiomay dramatically inﬂuence the equilib-
rium among those metabolites [10]. Experimental studies showed
that prostaglandin E1 (PGE1) suppresses leukocyte adhesion to the
sinusoidal endothelium of rodents and reduces the oxidative
stress-induced hepatocyte injury in cultured rat hepatocytes
[10]. Moreover, inhibition of PGE2 synthesis contributes also to
hepatocyte damage [10]. Inhibition of the powerful vasoactive
pro-inﬂammatory eicosanoid TXA2, in rats subjected to reperfu-
sion injury by selective blockage of TXA2 synthase or TXA2 recep-
tors, ameliorates liver necrosis, improves hepatic blood ﬂow, and
prolongs animal survival [28]. Likewise, intravenous administra-
tion of TXA2 synthase inhibitor in humans intra-operatively
reduces plasma TXB2 (a downstream metabolite of TXA2) and
blunts serum transaminase levels [29] In contrast to TXA2, PGI2
decreases platelet aggregation and leukocyte adhesion to the
endothelial surface. In rats, a PGI2 analog signiﬁcantly reduced
the hepatic microcirculatory defect after reperfusion, reduced leu-
kocyte adhesion, and improved blood ﬂow [10]. Therefore, nor-
malization of the X-6:X-3 FA ratio appears to be crucial for
protection of the steatotic liver from reperfusion injury. In human
LT, hepatic microcirculation was also signiﬁcantly altered in fatty
compared with lean liver grafts [30]. Impaired microcirculation at
the sinusoidal level may also be a decisive factor for blood supply
for the biliary tree. Accordingly, moderate to severe MaS wasTable 1. Reported data on liver transplantation using moderately steatotic (30–60%
Reference Year  Institution 
Zamboni et al. 
[69]
2001 Molinette Hospital 
Turin, Italy 
Verran et al. 
[7]
 2003  Royal Prince 
Alfred Hospital, Sydney
Australia
McCormack et al. 
[19]  
2007  Swiss HPB center,  
Zurich, Switzerland
Nickeghbalian et al. 
[70]  
2007  Nemazee Hospital 
Shiraz, Iran 
Angele et al. 
[5]
 2008 Klinikum Grosshader, 
Munich, Germany 
Li et al. 
[32]
2009 West China Hospital 
Chengdu, China
Frongillo et al. 
[71]
2009 Gemelli Hospidal 
Rome, Italy
Noujaim et al.
[40]
 2009  Hospital Beneficencia 
Portuguesa, San Paolo,
Brasil 
Gao et al. 
[72]
 2009 Zhejiang University
school of medecine
Hangzhou, China 
Doyle et al. 
[73]
 2010 Washington University 
University, St Louis, US 
Staining 
H&E
N/A 
H&E 
Sudan red
H&E 
H&E 
H&E 
H&E 
H&E 
N/A 
H&E 
PNF: primary graft non-function deﬁned as death or re-transplantation in the ﬁrst week a
deﬁned as death or re-transplantation within 4 months; +: PNF deﬁned as death or re-tran
moderate and severely steatotic livers; &: 4 months survival; #: predominant MaS (<10
Journal of Hepatology 2011found to be an independent risk factor for the development of bil-
iary complications after LT [31].Impact on early post-transplant outcome
Accumulating evidence from clinical and experimental observa-
tions indicates that steatosis in liver grafts increases complica-
tions after LT [19,32] [19,31] such as prolonged ICU stay,
hospital stay, the incidence of primary graft dysfunction or
non-function, and cost [30,50,60]. However, while there is gen-
eral agreement that mild steatosis (<30%) causes minor graft
injury, studies have been inconsistent regarding the relevance
of the higher degree of steatosis (>30%) or type of fat
[1,12,24,33–36]. For example, the primary non function rates
range between 0% and 75% in moderate graft steatosis (30–60%)
after LT (Table 1).
When the total amount of hepatic steatosis is more than 60%,
most transplant surgeons currently discard grafts because of an
expected high risk of graft failure (Table 2). By contrast, some
authors reported excellent results after transplantation using
markedly steatotic liver grafts. For example, a case control study
comparing 20 patients with severely steatotic grafts (median of
90% liver steatosis) with 40 matched patients without fatty grafts) grafts considering only the amount of macrosteatosis.
 
Macrosteatosis 
(%) 
>25
30-60 
30-60 
30-60 
30-60 
20-40 
30-60 
30-60 # 
30-60 
30-60 
No. 
grafts
8
25 
6 
34 
36 
18 
3 
6 
24 
22 
PNF 
rate 
(%)
75+  
0 
0 
18 $  
4* 
5.6 
33 
0 
0 
0 
12 months 
graft survival 
(%) 
N/A 
60 
100 
73 
77% &* 
89.7 
33 
50 
91.7 
81.5 
fter LT; H&E: hematoxylin and eosin staining technique; N/A, not assessed; $: PNF
splantation within 1 month; ⁄: data available only for a combined group involving
% of MiS). (See above-mentioned references for further information.)
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Table 2. Reported data on liver transplantation using severely steatotic (>60%) liver grafts of mixed type.
Reference noitutitsnIraeY Staining Mixed
steatosis
(%) 
No. 
grafts
PNF 
rate 
(%)
12 months 
graft survival 
(%) 
Todo et al. 
[74]
,hgrubsttiPfoytisrevinU9891
Pennsylvania, US 
O 06>der-O-li 2 001 0 
Adam et al.
[75]
,latipôHessuorBluaP1991
Villejuif, France 
A/N 06> 7 41 A/N
Markin et al.
]67[
aksarbeNfoytisrevinU3991
Medical Center, 
Omaha. US
Frozen 
H&E 
Oil-O-red
54> 22 Not 
transplanted
-  
Ploeg et al.
[77]
,nisnocsiWfoytisrevinU3991
Madison, US
A/N 06> 5 08 A/N
De Carli et al. 
]87[
,latipsoHadraugiN9991
Milan, Italy 
A/N 06> 12 66 A/N
Canelo et al.
]97[
,tatisrevinU-tsuguA-groeG9991
Gottingen, Germany 
A/N 06> 01 #04 A/N
McCormack et al.
[19]
,retnecBPHssiwS7002
Zurich, Switzerland 
E&H
dernaduS
06> 02 5 48
Frongillo et al.
]17[
,latipsoHillemeG9002
Rome, Italy
E&H 06> 3 33 0 
Noujaim et al. 
]04[
2009 Hospital Beneficencia, 
Portuguesa, San Paolo,
Brasil
E&H 06> 12 0 53
PNF: primary graft non-function deﬁned as death or re-transplantation in the ﬁrst week after LT; H&E: hematoxylin and eosin staining technique; N/A: not assessed; #: PNF
deﬁned as death or re-transplantation within 4 months. (See above-mentioned references for further information.)
Table 3. Reported data on liver transplantation using severely steatotic (>60%) grafts considering only the amount of microsteatosis.
Reference Year  Institution Staining Macrosteatosis 
(%) 
No. 
grafts
PNF 
rate 
(%)
12 months 
graft survival 
Fishbein et al.
[37]
1997 Mount Sinai Medical Center 
New York. US
N/A 06> 25 N/A N/A
Urena et al.
[80]
1998 University Hospital 12 
de Octubre, Madrid, Spain
IIInaduS 06> 2 0 A/N
Yoong et al.
[38]
1999 Queen Elizabeth Hospital, 
Birmingham, UK
A/N 66> 01 0§001
Zamboni et al. 
[69]
 2001 Molinette Hospital, 
Turin, Italy 
E&H 54> 6 A/N A/N
McCormack et al.
]91[
2007 Swiss HPB center, 
Zurich, Switzerland  
E&H
dernaduS
06> 01 01 09
Noujaim et al. 
[40]
 2009 Hospital Beneficencia
Portuguesa, San Paolo 
Brasil
E&H #06> 01 01 06
PNF: primary graft non-function deﬁned as death or re-transplantation in the ﬁrst week after LT; H&E: hematoxylin and eosin staining technique; N/A: not assessed; #:
predominant MiS (<10% of MaS); §: referred to graft failure with a median survival of 1.5 months. (See above-mentioned references for further information.)
Frontiers in Liver Transplantationshowed comparable 60-day post-transplant mortality (5% vs. 5%)
and 3-year patient survival rates (83% vs. 84%) [19]. Noteworthy,
all recipients disclosed a lowMELD (Model for end stage liver dis-
ease) score (median lab MELD 12 (range 6–25) (Table 2).1058 Journal of Hepatology 2011In addition to the controversial data available on the total
amount of hepatic fat, the inﬂuence of MiS vs. MaS in liver grafts
on outcome remains unclear. While some authors suggested that
livers with severe MiS can be safely used for LT [37], anothervol. 54 j 1055–1062
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study reported a 100% primary graft non-function rate when
severely steatotic grafts with MiS were used for re-transplanta-
tion [38] (Table 3). A recent study showed that MiS per se is an
independent donor factor inﬂuencing donor graft function [39].
Reports on transplanting livers with P60% of predominantly
MaS are scarce. Two studies showed 12 month survival of 58%
[7] and 25% (n = 5) [40]. The lack of agreement among patholo-
gists regarding evaluation of the type and degree of steatosis
[16] may explain the discrepancies among the studies.
The most recent and largest study on post-transplant outcome
of donor liver steatosis originates from the USA and refers to
5051 liver transplanted patients [21]. In this registry, the pres-
ence of more than 30% of macrosteatosis was found to be an inde-
pendent risk factor associated with lower one year graft survival
(relative risk 1.71). Importantly, when cold ischemia extended
beyond 11 h, also lower degrees of macrosteatosis (20%, 25%,
and 30%) were associated with an increased risk of graft loss (rel-
ative risk 1.51). The data additionally suggested that donor livers
with >30% MaS may be successfully used, if other donor risk fac-
tors are eliminated (e.g., donor age <40y, cold ischemia <5 h, no
donation after cardiac death) [21].
There are currently no guidelines for an optimal allocation of
steatotic liver grafts [35,41,42]. Most centers advocate the con-
cept that steatotic grafts should be directed only to candidates
in relatively good clinical condition but higher need of LT (e.g.,
cirrhotic patients with hepatocarcinoma having MELD <25), and
avoid using them for recipients with fulminant liver failure or
re-transplantation [19,43,44]. This strategy is based on the ratio-
nale that healthier recipients could better tolerate a poor initial
graft function or major post-operative complications [33,45,46].
However, caution must be taken in using low quality organs for
less urgent patients with questionable survival beneﬁt of LT since
they could eventually wait longer for a better organ [47]. In con-
clusion, an appropriate balance between donor age, graft MaS,
graft ischemia time, and also recipient MELD appears decisive
for outcome after liver transplantation [21].
While these results are valid for deceased donor liver trans-
plantation, the experience of using fatty liver grafts for living
donor liver transplantation is scarce and hepatic steatosis is usu-
ally regarded as a contraindication for living donation in most
centers [48]. However, the regeneration ability of the fatty liver
is controversially discussed [49,50]. Whether potential donors
with mild steatosis should be completely denied from live dona-
tion depends, therefore, also on graft volume and donor age. In
cases with no other risk factors, a steatosis degree up to 15%
appears acceptable.Impact of graft steatosis on long-term outcome after LT
Recipients receiving a fatty liver, show a dramatic decrease in
fatty inﬁltration shortly after LT [6,19,32]. The mechanism of this
phenomenon remains elusive, but may have important conse-
quences for the long-term outcome. Independent factors that
negatively affect this reversal of steatosis were donor age
(>50 years) and prolonged cold ischemia time (>12 h) [32]. Corre-
sponding to the fat changes in transplanted liver grafts, the
presence of moderate to severe MaS before LT did not affect
long-term organ survival [5].
Besides these results, LT recipients are particularly at risk for
de novo development of NAFLD as they cumulate several riskJournal of Hepatology 2011factors. For example, cyclosporine has been associated with a
high incidence of hypertension and hyperlipemia, and tacrolimus
or sirolimus may cause a variety of adverse effects, including dia-
betes mellitus [51,52]. Moreover, LT recipients are subject to
major changes in nutritional status, especially those with history
of alcoholic disease, which may contribute to some metabolic
dysfunctions [9]. The grafts itself may contribute to the patho-
genesis of NAFLD, as its own personal history and genetic predis-
position may inﬂuence its response to the new and different
environment provided by the recipient. In this scenario, weight
management, prevention and treatment of post-LT obesity, cor-
rection of metabolic syndrome, and long-term close monitoring
might help minimizing the risk of occurrence of post-transplant
steatosis [53].
Interestingly, an Italian group recently demonstrated that
transplanting livers with moderate to severe MaS is an indepen-
dent risk factor for the development of biliary complications after
LT [31]. Perhaps, an impaired microcirculation at the sinusoidal
level could be responsible for bile duct ischemic damage, result-
ing in a higher risk of biliary strictures. However, this initial
hypothesis needs further investigation.
Steatosis in the liver graft has been identiﬁed as a negative
prognostic factor for HCV recurrence [54–56]. Donor age limita-
tion and exclusion of moderately to severely steatotic livers were
proposed to minimize the severity of HCV recurrence [57]. How-
ever, given the fact that steatosis disappears early after LT, there
is no obvious mechanism by which steatosis in the liver graft syn-
ergizes HCV recurrence after LT. In contrast with previous data, a
recent study suggested that steatotic grafts do not exacerbate the
progression of ﬁbrosis nor negatively affect long-term survival in
HCV recipients [58]. The literature is divided on the effect of
donor graft steatosis as a facilitator or stimulator of ﬁbrosis on
patients with post-LT HCV recurrence [33,54,58]. Longer follow-
up studies are necessary to clarify the effect of allograft steatosis
in the natural history of HCV recurrence [59].Strategies to improve outcome after transplantation of
steatotic livers
The key strategy to optimize results when using fatty liver grafts
is to minimize other risk factors. In this context, cold and warm
ischemia time must be shortened as much as possible. Some
promising approaches preventing activation of the inﬂammatory
cascade are under investigations in a number of experimental
and clinical protocols, such as attenuation of cytokine activation
(mitogen activated protein kinase, MAPK), blockade of endothelin
receptors, modulation of the heme oxygenase system, or inhibi-
tion of mitochondrial dysfunction [60,61]. The use of machine-
based liver perfusion systems may also offers beneﬁts and
perhaps a way to test the function of the organ prior to implan-
tation. The new preservation concepts include in situ warm oxy-
genated perfusion before harvest (normothermic concept) [62] or
hypothermic machine perfusion after organ procurement and
transport to the transplantation center (hypothermic concept)
[63–67]. While the perfusion system may enable to determine
the viability potential of the graft, wide application of perfusion
system in marginal graft such as severe steatotic livers will need
long-term data after LT.
Manipulation of the chemical composition of hepatic lipids
may evolve as a useful strategy to expand the donor pool andvol. 54 j 1055–1062 1059
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improve the outcome after LT. We have recently treated three
live liver donors with moderate degrees of steatosis by oral
administration ofX-3 FAs. All donors showed a signiﬁcant reduc-
tion of hepatic fatty inﬁltration within one month. Subsequently,
LT was carried out for three candidates with uneventful outcomes
for both donors and recipients [68].Summary
Steatosis is common in liver grafts and causes reperfusion
injury, regardless of the type of steatosis. Due to large inconsis-
tencies in the qualitative and quantitative measurement of fat
deposits in the liver, new techniques of assessment of steatosis
are needed. A very promising option to prevent post-transplant
complications appears to be the use of a pretreatment with X-
3 FAs. This approach is only feasible in living donation since it
requires oral administration of X-3 FAs before organ procure-
ment. However, machine liver perfusion of any liver graft with
X-3 FAs before implantation may emerge as an easily applica-
ble method to reverse an abnormal X-3:X-6 fatty acids ratio
and decrease reperfusion injury. Currently, in deceased donors,
the only effective strategy for the safe use of steatotic grafts is
based on the concept of minimizing other donor and recipient
risk factors. In this context, donor age below 40 years and a
cold storage beyond 5 h were shown to be protective in com-
bination with up to 30% of graft MaS. In addition, the general
condition of the recipient is likewise the single most important
factor (MELD <25). More than 60% of MaS in liver grafts bears a
signiﬁcant risk for decreased graft survival, regardless of other
risk factors.
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